Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis by Bertoldi I, Caporali R

Get full text

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence by Iannone F, Conti F, Cauli A, Farina A, Caporali R

Get full text

Regulatory role of CCL21 in the recruitment and exit of immune cells in rheumatoid synovium by Manzo, A, Bugatti, S, Buckley, C, Jackson, D, Caporali, R, Montecucco, C, Pitzalis, C

CCL21 relationship with lymphoid neogenesis and lymphatic vascular system in chronically inflamed synovium by Manzo, A, Bugatti, S, Buckley, C, Jackson, D, Caporali, R, Montecucco, C, Pitzalis, C

Relationship between CCL21 production and synovial vascular system in rheumatoid arthritis by Manzo, A, Bugatti, S, Buckley, C, Jackson, D, Caporali, R, Montecucco, C, Pitzalis, C

A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies Af... by Caporali, R, Kadakia, A, Howell, O, Patel, J, Milligan, J, Strengholt, S, Barlow, S, Taylor, PC

A real-world comparison of clinical effectiveness in patients with rheumatoid arthritis treated with upadacitinib, tumor necrosis factor inhibitors, and other advanced therapies af... by Caporali, R, Kadakia, A, Howell, O, Patel, J, Milligan, J, Strengholt, S, Barlow, S, Taylor, PC

Association between age at diagnosis and clinical presentation and outcomes of anca-associated vasculitis. analysis from the dcvas study by Monti, S, Craven, A, Klersy, C, Montecucco, C, Caporali, R, Watts, R, Merkel, PA, Luqmani, R

Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment by Caporali, R, Aletaha, D, Sanmarti, R, Takeuchi, T, Mo, D, Haladyj, E, Zaremba-Pechmann, L, Taylor, PC

CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis. by Manzo, A, Bugatti, S, Caporali, R, Prevo, R, Jackson, D, Uguccioni, M, Buckley, C, Montecucco, C, Pitzalis, C

Endothelial CCL21 production in rheumatoid synovivtis is restricted to the lymphatic system, which can proliferate, up-regulate CCL21 expression and mediate cell transport by Manzo, A, Bugatti, S, Caporali, R, Prevo, R, Jackson, D, Uguccioni, M, Buckley, C, Montecucco, C, Pitzalis, C

Characterization of CCL21 expression in human secondary lymphoid organs and ectopic lymphoid tissues by Bugatti, S, Manzo, A, Caporali, R, Prevo, R, Jackson, D, Uguccioni, M, Buckley, C, Montecucco, C, Pitzalis, C

Mode of administration in rheumatoid arthritis treatments: an exploration of patient preference for an 'ideal treatment' by Taylor, PC, Alten, R, Jesus Gomez-Reino, J, Caporali, R, Bertin, P, Grant, L, Brohan, E, Wells, J, Vasilescu, R, Tarallo, M

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study by Caporali, R, Taylor, PC, Aletaha, D, Sanmartí, R, Takeuchi, T, Mo, D, Haladyj, E, Bello, N, Zaremba-Pechmann, L, Fang, Y, Dougados, M

"I am always in pain somewhere": Continuing unmet need in rheumatoid arthritis by Taylor, PC, Alten, R, Jesus Gomez-Reino, J, Caporali, R, Bertin, P, Grant, L, Brohan, E, Wells, J, Vasilescu, R, Tarallo, M

Physician and patient attitudes towards treat-to-target, its implementation and stated treatment goals in patients with rheumatoid arthritis in a real-world setting across Europe by Fautrel, B, Caporali, R, Holdsworth, E, Donaghy, B, Khalid, M, Moore, M, Van Beneden, K, Piette, Y, Romero-Yuste, S, Broen, J, Taylor, PC

Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice by Taylor PC, Alten R, Gomez Reino JJ, Caporali R, Bertin P, Sullivan E, Wood R, Piercy J, Vasilescu R, Spurden D, Alvir J, Tarallo M

Get full text

Comparison of biologic disease-modifying anti-rheumatic drug rheumatoid arthritis treatment dynamics across five European Union countries by Taylor, P, Alten, R, Gomez-Reino, J, Caporali, R, Bertin, P, Sullivan, E, Wood, R, Piercy, J, Vasilescu, R, Spurden, D, Alvir, J, Tarallo, M

Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity, and... by Taylor, PC, Fautrel, B, Piette, Y, Romero-Yuste, S, Broen, J, Welcker, M, Howell, O, Rottier, E, Zignani, M, Van Beneden, K, Caporali, R, Alten, R

Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice by Taylor, P, Alten, R, Gomez Reino, J, Caporali, R, Bertin, P, Sullivan, E, Wood, R, Piercy, J, Vasilescu, R, Spurden, D, Alvir, J, Tarallo, M